T1	Participants 0 81	Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched
T2	Participants 91 111	donor allogeneic HCT
T3	Participants 131 163	graft-versus-host disease (GVHD)
T4	Participants 188 223	35% of matched, related donor (MRD)
T5	Participants 235 275	hematopoietic cell transplantation (HCT)
T6	Participants 583 690	114-day grades 2-4 acute GVHD-free survival using an intention-to-treat analysis of 304 randomized subjects
T7	Participants 721 781	e probability of day 114 grades 2-4 acute GVHD-free survival
T8	Participants 114 124	Grades 2-4
T9	Participants 1010 1068	Oropharyngeal mucositis was less severe in the Tac/Sir arm
T10	Participants 1215 1279	overall survival at 2 years were no different between study arms
T11	Participants 333 367	tacrolimus and sirolimus (Tac/Sir)
T12	Participants 1555 1702	National Heart, Lung, and Blood Institute and the National Cancer Institute; and the trial was registered at www.clinicaltrials.gov as #NCT00406393
T13	Participants 1366 1524	long-term outcomes, more rapid engraftment, and less oropharyngeal mucositis, the combination of Tac/Sir is an acceptable alternative to Tac/Mtx after MRD HCT
